FDA Rules Out Suicide Risk for GLP-1 Weight-Loss Drugs

On January 13, 2026, the U.S. Food and Drug Administration (FDA) formally requested that manufacturers remove existing information about the risk of suicidal thoughts and behaviors from the labeling of Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide). This move follows a comprehensive safety review of the drug class GLP-1 - made famous by weight-loss injections like Wegovy and diabetes medications like Ozempic - that found no increased risk of suicidal thoughts or actions. The previously investigated red flag in the adverse event data (in technical terms: the so-called 'SI/B signal') concerning suicidal ideation and behavior linked to the GLP-1 receptor agonists (drugs that activate the GLP-1 docking point in the body) has been definitively ruled out.

What data did the FDA review?

The FDA evaluated 91 placebo-controlled trials - studies in which one group received the real medication and a comparison group received an inactive dummy pill (placebo) - as well as a large claims-based cohort study (a long-term analysis of health insurance data, comparing real patients with and without GLP-1 use over several years), data that had already been included in the agency's preliminary review from January 2024. The conclusion: no statistically meaningful link emerged - in plain terms, the data showed no pattern beyond what chance alone would produce - between GLP-1 use and suicidal ideation, suicide attempts, or other psychiatric events. The European Medicines Agency (EMA) had already reached the same conclusion in April 2024 after its own investigation.

What does this mean for patients?

The FDA emphasizes that healthcare professionals and patients should be informed about the updated evidence. Under this decision, the existing warnings about suicidal behavior and ideation will be removed from product labeling - eliminating language that patients and providers have previously encountered when reviewing these medications. The safety assessment is now uniform across all GLP-1 products. Diabetes medications such as Ozempic and Mounjaro were never the subject of an SI/B signal. The agency continues to recommend monitoring mental health changes but states clearly: current data does not support an elevated psychiatric risk.

Background: How did the review originate?

In 2024, the FDA's Adverse Event Reporting System (a database where suspected side-effect cases are reported) received isolated reports of suicidal thoughts from GLP-1 users, prompting the agency to investigate the signal - that is, the suspicion of a previously unknown risk. Because the data remained inconclusive at the time, the relevant labeling language about suicidal ideation was kept in place. This signal was never confirmed in clinical trials or observational studies. The FDA had published a preliminary review in January 2024 but could not rule out a residual risk at that time. The now-completed final assessment of that same dataset allows for a definitive conclusion and has triggered the current request to remove the warnings.

Learn more about GLP-1 safety aspects in the Semaglutide profile and the article on GLP-1 dosing errors and poison control surges.

Not medical advice: This article is for informational purposes only and does not replace individual medical consultation. Consult your healthcare provider for questions about GLP-1 medications.